Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Trial Profile

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs Inotuzumab ozogamicin (Primary)
  • Indications Lymphoid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Oct 2018 Status changed from suspended to recruiting.
    • 02 Aug 2018 Planned End Date changed from 1 Oct 2020 to 1 May 2021.
    • 02 Aug 2018 Planned primary completion date changed from 1 Oct 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top